USO 24265

A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (GO45434)

Disease Types: Leukemia & Lymphoma Research

Eligibility Requirements:

Histologically confirmed DLBCL, not otherwise specified (NOS)
R/R disease, defined as: relapsed = disease that has recurred following a response that lasted >/= 6 months after completion of the last line of therapy; refractory = disease that did not respond to or that progressed < 6 months after completion of the last line of therapy
At least one line of prior systemic therapy
Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (> 1 cm) extranodal lesion, as measured on CT scan
Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2
Adequate hematologic and renal function

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Virginia Beach (Princess Anne)
• Williamsburg
• Norfolk (Brock Cancer Center)